Utilization of Stiripentol in Children With Developmental and Epileptic Encephalopathies: Considerations for Clinical Practice
Open Access
- 27 March 2026
- journal article
- review article
- Published by Elsevier in Pediatric Neurology
- Vol. 179, 123-132
Abstract
No abstract availableKeywords
This publication has 77 references indexed in Scilit:
- Stiripentol: Unpublished results from the first phase 2 clinical trial in Lennox–Gastaut syndrome conducted in the early 1990sEpilepsia, 2026
- Refining management strategies for Lennox–Gastaut syndrome: Updated algorithms and practical approachesEpilepsia Open, 2024
- Efficacy and safety of stiripentol in the prevention and cessation of status epilepticus: A systematic reviewEpilepsia Open, 2024
- The impact of developmental and epileptic encephalopathies on families: a qualitative studyEuropean Journal of Pediatrics, 2024
- Efficacy of anti‐seizure medications and alternative therapies (ketogenic diet, CBD, and quinidine) in KCNT1‐related epilepsy: A systematic reviewEpilepsia Open, 2024
- Additional Results from Two Randomized, Placebo-Controlled Trials of Stiripentol in Dravet Syndrome Highlight a Rapid Antiseizure Efficacy with Longer Seizure-Free PeriodsNeurology and Therapy, 2024
- An Update on Stiripentol Mechanisms of Action: A Narrative ReviewAdvances in Therapy, 2024
- Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first‐line add‐on therapies for seizures in Dravet syndrome: A network meta‐analysisEpilepsia Open, 2024
- Efficacy and tolerability of add‐on stiripentol in real‐world clinical practice: An observational study in Dravet syndrome and non‐Dravet developmental and epileptic encephalopathiesEpilepsia Open, 2023
- Status epilepticus and early development: Neuronal injury, neurodegeneration, and their consequencesEpilepsia Open, 2022